UK markets open in 2 hours 15 minutes
  • NIKKEI 225

    28,030.91
    -131.92 (-0.47%)
     
  • HANG SENG

    18,004.67
    +706.73 (+4.09%)
     
  • CRUDE OIL

    78.95
    +1.71 (+2.21%)
     
  • GOLD FUTURES

    1,752.60
    +12.30 (+0.71%)
     
  • DOW

    33,849.46
    -497.57 (-1.45%)
     
  • BTC-GBP

    13,718.19
    +175.86 (+1.30%)
     
  • CMC Crypto 200

    388.80
    +8.51 (+2.24%)
     
  • ^IXIC

    11,049.50
    -176.86 (-1.58%)
     
  • ^FTAS

    4,098.49
    -13.82 (-0.34%)
     

Novo Nordisk to increase manufacturing capacity of weight-loss drugs

FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen

FRANKFURT (Reuters) - Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.

"As we look to launch future products, obviously we will take into consideration more of a 'pull' than a 'push' commercial strategy. And that links into how we scale capacity for that," Chief Executive Lars Fruergaard Jorgensen told journalists in a call on nine-month results.

"We see this pull nature in the market for anti-obesity medicine, which is fantastic because we have the broadest portfolio in the industry to do that," he added.

The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year.

(Reporting by Ludwig Burger, Editing by Louise Heavens)